» Articles » PMID: 27217054

Sepsis: Pathophysiology and Clinical Management

Overview
Journal BMJ
Specialty General Medicine
Date 2016 May 25
PMID 27217054
Citations 465
Authors
Affiliations
Soon will be listed here.
Abstract

Sepsis, severe sepsis, and septic shock represent increasingly severe systemic inflammatory responses to infection. Sepsis is common in the aging population, and it disproportionately affects patients with cancer and underlying immunosuppression. In its most severe form, sepsis causes multiple organ dysfunction that can produce a state of chronic critical illness characterized by severe immune dysfunction and catabolism. Much has been learnt about the pathogenesis of sepsis at the molecular, cell, and intact organ level. Despite uncertainties in hemodynamic management and several treatments that have failed in clinical trials, investigational therapies increasingly target sepsis induced organ and immune dysfunction. Outcomes in sepsis have greatly improved overall, probably because of an enhanced focus on early diagnosis and fluid resuscitation, the rapid delivery of effective antibiotics, and other improvements in supportive care for critically ill patients. These improvements include lung protective ventilation, more judicious use of blood products, and strategies to reduce nosocomial infections.

Citing Articles

Enhanced epigenetic modulation via mRNA-encapsulated lipid nanoparticles enables targeted anti-inflammatory control.

Mokhtari T, Taheri M, Akhlaghi S, Aryannejad A, Xiang Y, Mahajan V bioRxiv. 2025; .

PMID: 40060445 PMC: 11888353. DOI: 10.1101/2025.02.24.639996.


The impact of pharmacist-led education and prospective audit and feedback on antibiotic dose optimization within medical intensive care units in Thailand: a retrospective study.

Gatechan T, Nakaranurack C, Plongla R, Chuenjit T, Gross A J Pharm Policy Pract. 2025; 18(1):2467456.

PMID: 40034877 PMC: 11873917. DOI: 10.1080/20523211.2025.2467456.


Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies.

Zhang X, Zhang W, Zhang H, Liao X Front Immunol. 2025; 16:1546474.

PMID: 40013154 PMC: 11862915. DOI: 10.3389/fimmu.2025.1546474.


Tocilizumab in treating children with refractory septic shock.

Lee E, Chen S, Wu H Crit Care. 2025; 29(1):87.

PMID: 39994755 PMC: 11853752. DOI: 10.1186/s13054-025-05318-6.


Low apolipoprotein A-II levels causally contribute to increased mortality in septic shock.

Takahashi N, Campbell K, Shimada T, Nakada T, Russell J, Walley K J Intensive Care. 2025; 13(1):10.

PMID: 39980010 PMC: 11841007. DOI: 10.1186/s40560-025-00782-2.